CLINICAL_TRIALS trial_result · 2014-04-21

Clinical Trial Update: Long-term Study of Alogliptin as an Add-on to Rapid-Acting Insulin Secretagogues in Type 2 Diabetes [Phase 3]

A long-term Phase 3 trial evaluating alogliptin added to rapid-acting insulin secretagogues in Type 2 diabetes has completed and results were posted.

Upgrade for the full analysis, importance score, and drug timeline.

Sponsor: Takeda | Conditions: Diabetes Mellitus | Phase 3 | Status: COMPLETED | Results posted: 2014-04-21